GeoVax Labs Inc. (NASDAQ:GOVX) Sees Significant Drop in Short Interest

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totaling 1,514,630 shares, a drop of 51.5% from the December 15th total of 3,124,146 shares. Based on an average daily volume of 6,248,406 shares, the days-to-cover ratio is presently 0.2 days. Approximately 5.1% of the company’s shares are short sold. Approximately 5.1% of the company’s shares are short sold. Based on an average daily volume of 6,248,406 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

A number of research analysts have recently commented on GOVX shares. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Wednesday, October 8th. D. Boral Capital dropped their target price on shares of GeoVax Labs from $225.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $187.50.

GeoVax Labs Trading Down 15.8%

Shares of GOVX traded down $0.55 during mid-day trading on Wednesday, hitting $2.93. The company’s stock had a trading volume of 244,817 shares, compared to its average volume of 196,373. The company’s 50-day moving average is $8.09 and its 200-day moving average is $13.60. GeoVax Labs has a 52-week low of $2.87 and a 52-week high of $57.88. The firm has a market capitalization of $3.52 million, a price-to-earnings ratio of -0.08 and a beta of 3.67.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Thursday, November 13th. The company reported ($7.75) EPS for the quarter, missing analysts’ consensus estimates of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. As a group, sell-side analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Trading of GeoVax Labs

Several large investors have recently bought and sold shares of the stock. Sabby Management LLC purchased a new position in shares of GeoVax Labs during the 3rd quarter valued at approximately $313,000. Hudson Bay Capital Management LP purchased a new position in GeoVax Labs in the third quarter valued at $47,000. Armistice Capital LLC acquired a new position in shares of GeoVax Labs in the third quarter worth about $253,000. Finally, Jane Street Group LLC purchased a new stake in shares of GeoVax Labs during the 1st quarter worth about $27,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.